Rare Disease Initiatives. Newborn Screening.. Orphan Drug Act. FDA Modernization. FDA Initiatives.
2026 · 3rd Quarter (July 1 - Sep 30)
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD)
Filed by NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD).
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 20, 2026
- Income
- Not reported
- Expenses
- $70,000.00
- Filing UUID
- e167fbf1-b86d-4b7e-95a1-aac55d6b3828
- Termination date
- Not reported
Expense method: B
Literal source text
Lobbying issues and bill citations
Pharmaceutical issues impacting patients with rare diseases. Prescription Drug User Fee Act (PDUFA) Reauthorization. User Fee Agreements. Patient Experience Data.
Appropriations impacting patients with rare diseases. National Institutes of Health (NIH) NCATS Appropriations. Legislation on Accepting User Fees during a Lapse in Government Funding.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.